Taysha Gene Therapies Net Cash Flow 2020-2024 | TSHA
Taysha Gene Therapies net cash flow from 2020 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Taysha Gene Therapies Annual Net Cash Flow
(Millions of US $) |
| 2024 |
$-5 |
| 2023 |
$56 |
| 2022 |
$-61 |
| 2021 |
$-100 |
| 2020 |
$251 |
| 2019 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.398B |
$0.008B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
